{
    "id": 8569,
    "fullName": "CDKN2C del",
    "impact": "deletion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CDKN2C del indicates a deletion of the CDKN2C gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1031,
        "geneSymbol": "CDKN2C",
        "terms": [
            "CDKN2C",
            "INK4C",
            "p18",
            "p18-INK4C"
        ]
    },
    "variant": "del",
    "createDate": "07/02/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9367,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A and CDKN2C in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 8470,
                "profileName": "CDKN2A del CDKN2C del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2501,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human glioblastoma cell lines with a CDKN2A/CDKN2C codeletion demonstrated sensitivity to Palbociclib (PD0332991) (PMID: 20534551).",
            "molecularProfile": {
                "id": 8470,
                "profileName": "CDKN2A del CDKN2C del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3184,
                    "pubMedId": 20534551,
                    "title": "Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20534551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9365,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A and hemizygous deletion of CDK4 in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 26837,
                "profileName": "CDK4 pos CDKN2C del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8470,
            "profileName": "CDKN2A del CDKN2C del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11039,
            "profileName": "CDKN2C del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26837,
            "profileName": "CDK4 pos CDKN2C del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}